SCHEMBL20183890

SCHEMBL20183890

CS(=O)(=O)OCC#Cc1ccc(C(=O)N2CCCCC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 8/20 0.51
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
ACACB O00763 2/20 0.48
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
MAPT P10636 1/20 0.46
LMNA P02545 1/20 0.46
GRM3 Q14832 1/20 0.46
HSD17B10 Q99714 1/20 0.45
GRM5 P41594 1/20 0.44
EGLN1 Q9GZT9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20183911 0.88 HPGD (0.50) HPGDALDH1A1KDM4EL3MBTL1ACACB
SCHEMBL20183906 0.84 MEN1 (0.52) MEN1KMT2ASMN1; SMN2MAPTLMNA
SCHEMBL20183914 0.78 HPGD (0.62) HPGDALDH1A1KDM4EL3MBTL1ACACB
SCHEMBL20183922 0.76 MMP2 (0.31) LMNAGRM3GRM5
SCHEMBL31497569 0.75 HPGD (0.67) HPGDALDH1A1KDM4EL3MBTL1ACACB
SCHEMBL31497563 0.73 HPGD (0.79) HPGDALDH1A1KDM4EL3MBTL1SMN1; SMN2
SCHEMBL20183877 0.73 L3MBTL1 (0.46) HPGDALDH1A1L3MBTL1MEN1KMT2A
SCHEMBL16151536 0.71 HPGD (0.65) HPGDALDH1A1KDM4EL3MBTL1ACACB
SCHEMBL6563119 0.71 ACACB (0.49) HPGDALDH1A1KDM4EL3MBTL1ACACB
SCHEMBL27479149 0.71 HPGD (1.00) HPGDALDH1A1L3MBTL1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10766857-B2 Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2020-09-08 US disclosed
EP-3327000-B1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT UNIV DONGGUK IND ACAD COOP (KR) 2020-09-02 EP disclosed
US-20190071395-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2019-03-07 US disclosed
US-10179764-B2 Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2019-01-15 US disclosed
US-20180201573-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2018-07-19 US disclosed
EP-3327000-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT Dongguk University Industry-Academic Cooperation Foundation (KR) 2018-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180201573-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT LTB4R2, CYSLTR2, LTB4R HPGD 1789/4885ALDH1A1 3365/4885KDM4E 3685/4885
US-10766857-B2 Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient LTB4R2, CYSLTR2, LTB4R HPGD 1773/4885ALDH1A1 3336/4885KDM4E 3585/4885
US-10179764-B2 Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient LTB4R2, CYSLTR2, LTB4R HPGD 1773/4885ALDH1A1 3336/4885KDM4E 3585/4885
US-20190071395-A1 NOVEL COMPOUND HAVING BLT INHIBITORY ACTIVITY AND COMPOSITION, FOR PREVENTING OR TREATING INFLAMMATORY DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT LTB4R2, CYSLTR2, LTB4R HPGD 1789/4885ALDH1A1 3365/4885KDM4E 3685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.